The role of the c-Jun N-terminal kinase (JNK) pathway in insulin resistance

Publication date

2016-11-14T10:00:08Z

2016-11-14T10:00:08Z

2016

Abstract

Podeu consultar el llibre complet a: http://hdl.handle.net/2445/103042


Obesity is usually associated with a decreased response to insulin, a major metabolic defect known as insulin resistance and an early trait in the development of type 2 diabetes. The c-Jun N-terminal kinase (JNK) pathway has emerged as a central regulator of insulin sensitivity, locally and systemically, thereby, of body’s metabolic homeostasis. As the incidence of obesity and type 2 diabetes has alarmingly increased in the last few decades, there is a tremendous necessity to identify novel pharmacological targets to efficiently improve the therapeutic outcome. In this regard, the JNK pathway seems to meet most of the requirements for being an adequate candidate to direct pharmacological intervention.

Document Type

Chapter or part of a book


Published version

Language

English

Publisher

Research Signpost

Related items

Reproducció del capítol del llibre publicat a: http://www.trnres.com/ebookcontents.php?id=267

Recent Advances in Pharmaceutical Sciences VI, 2016, Research Signpost. Editors: Diego Muñoz Torrero, Àngela Domínguez García & Ma. Ángeles Manresa Presas. ISBN: 978-81-308-0566-5. Chapter 5, p. 76-90.

http://hdl.handle.net/2445/103042

Recommended citation

This citation was generated automatically.

Rights

(c) Research Signpost, 2016

This item appears in the following Collection(s)